Skip to main content
    S

    Sol Gel Technologies Ltd (SLGL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $68.30
    -4.10 (-5.66%)

    Market Cap: $227.54M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(24/35)
    Avg Surprise
    +18.31%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-2.27
    Range$-3.01 - $-1.54
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-3.45+34.1%
    60d ago$-2.58+11.8%
    30d ago$-3.01+24.4%
    7d ago$-3.01+24.4%
    Current$-2.27
    Revenue Consensus
    $300000
    Range$300000 - $300000
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.28
    Range$-4.33 - $1.76
    2 analysts
    Revenue Consensus
    $-1000
    Range$-1000 - $-1000
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.28---
    Sep 26EST
    		-$-2.27---
    Jun 26
    Reported Aug 20
    		$-1.13N/A+51.08%Beat-127.1%
    Mar 26
    Reported May 28
    		$-1.31$-1.63+19.63%Beat-524.1%
    Dec 25
    Reported Mar 19
    		$-1.06$0.40-365.00%Miss-10500.0%
    Sep 25
    Reported Nov 20
    		$-2.13$-2.09-1.91%Miss-2030.0%
    Jun 25
    Reported Aug 15
    		$4.17$-0.70+695.71%Beat+495.7%
    Mar 25
    Reported Apr 29
    		$-0.21$-0.12-74.92%Miss+8.7%
    Dec 24
    Reported Mar 26
    		$-0.01N/A+90.91%Beat+99.4%
    Sep 24
    Reported Nov 15
    		$-0.10N/A+80.00%Beat+95.2%
    Jun 24
    Reported Aug 16
    		$0.70N/A+136.84%Beat+131.8%
    Mar 24
    Reported May 20
    		$-0.23$-0.15-53.33%Miss+94.4%
    Dec 23
    Reported Mar 13
    		$-1.70$-1.75+2.86%Beat-580.0%
    Sep 23
    Reported Nov 9
    		$-2.10$-2.30+8.70%Beat-40.0%
    Jun 23
    Reported Aug 10
    		$-2.20$-2.55+13.73%Beat-2100.0%
    Mar 23
    Reported May 12
    		$-4.10$-2.15-90.70%Miss-70.8%
    Dec 22
    Reported Mar 10
    		$-0.25$-0.12-108.33%Miss-141.0%
    Sep 22
    Reported Nov 10
    		$-1.50$-0.65-130.77%Miss-400.0%
    Jun 22
    Reported Aug 4
    		$-0.10N/A+89.69%Beat+97.1%
    Mar 22
    Reported May 13
    		$-2.40$-2.90+17.24%Beat-33.3%
    Dec 21
    Reported Mar 30
    		$0.61$0.41+48.78%Beat+317.9%
    Sep 21
    Reported Nov 11
    		$0.50N/A+115.15%Beat+113.5%
    Jun 21
    Reported Aug 4
    		$-3.50$-1.83-91.26%Miss-12.9%
    Mar 21
    Reported May 13
    		$-1.80N/A+60.61%Beat+45.5%
    Dec 20
    Reported Mar 4
    		$-0.28$-0.41+31.71%Beat+15.2%
    Sep 20
    Reported Nov 12
    		$-3.70$-5.17+28.43%Beat+0.0%
    Jun 20
    Reported Aug 6
    		$-3.10$-3.77+17.77%Beat-19.2%
    Mar 20
    Reported May 14
    		$-3.30$-4.00+17.50%Beat-1000.0%
    Dec 19
    Reported Mar 24
    		$-0.33$-0.34+2.94%Beat+94.8%
    Sep 19
    Reported Nov 13
    		$-3.70$-2.60-42.31%Miss+7.5%
    Jun 19
    Reported Aug 13
    		$-2.60$-2.77+6.14%Beat+27.8%
    Mar 19
    Reported May 22
    		$-0.30$-0.60+50.00%Beat+92.3%
    Dec 18
    Reported Mar 21
    		$-6.40$-5.85-9.40%Miss-635.6%
    Sep 18
    Reported Nov 13
    		$-4.00$-5.72+30.07%Beat+45.9%
    Jun 18
    Reported Aug 8
    		$-3.60$-5.10+29.41%Beat-407.0%
    Mar 18
    Reported May 15
    		$-3.90$-4.17+6.47%Beat-1047.1%
    Dec 17
    Reported Feb 2
    		$-0.87$-0.61-42.62%Miss-
    Sep 17
    Reported Nov 29
    		$-7.40$0.00N/AMiss-
    Jun 17
    Reported Aug 29
    		$-0.71$0.00N/AMiss-
    Mar 17
    Reported Jun 29
    		$-0.34$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-12.13EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-704.00%
    ROE-40.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio10.37xQuick Ratio10.37x
    Trading Statistics
    Beta1.15Avg Volume43.20K
    52-Week High$97.9752-Week Low$28.81

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$72.86
    SMA 20$68.29
    SMA 50$72.85
    SMA 200$72.96
    EMA 10$71.09
    EMA 20$70.42
    EMA 50$71.71
    EMA 200$66.84

    MACD

    Line: 0.42Signal: 0.02Hist: 0.39

    ADX

    ADX: 19.7+DI: 25.6-DI: 22.5

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down36.0
    PSAR$78.74

    Bollinger Bands

    Upper Band$80.23
    Lower Band$56.35
    %B Position3497%(Upper)
    Band Width0.50

    RSI (14-Day)

    Neutral
    46.4

    Momentum Oscillators

    Stoch %K58.8
    Stoch %D60.8
    Williams %R-53.1
    ROC (10d)-5.5%
    Momentum-3.95
    CCI (20d)22.0
    MFI (14d)56.6

    Volatility Measures

    ATR (14d)$4.48(6.6%)
    StdDev (20d)5.97
    Hist Vol71.9%(High)

    Volume Flow

    VWAP$69.80
    OBV7.4M
    AD Line337.9M
    CMF (20d)0.021

    Volume Metrics

    Avg Vol (20d)43.2K
    Vol Ratio0.8x
    VWMA (20d)$67.12

    Pivot Points

    R3$77.45
    R2$75.28
    R1$73.84
    Pivot Point$71.67
    S1$70.23
    S2$68.06
    S3$66.62

    Advanced Oscillators

    TSI2.59
    Ultimate Osc56.5
    KST29.06

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$591,000$108,000$696,000$400,000$17.26M$1.03M$278,000$5.36M$5.43M$466,000$447,000$213,000
    Cost of RevenueN/AN/AN/AN/AN/A$278,000N/A$-7,828,000$2.44M$5.34M$4.17M$4.67M
    Gross Profit$591,000$108,000$696,000$400,000$17.26M$1.03MN/A$5.36M$5.43M$466,000$-3,724,000$213,000
    Operating Expenses$4.75M$3.96M$4.11M$6.69M$6.03M$10.10M$6.38M$6.19M$3.81M$-6,246,000$1.68M$6.52M
    R&D$3.72M$2.79M$3.58M$5.73M$4.65M$8.84M$5.20M$4.82M$2.44M$5.34M$4.17M$4.67M
    SG&A$1.03M$1.18M$577,000$957,000$1.39M$1.26M$1.18M$1.37M$1.37M$1.83M$1.72M$1.86M
    Operating Income$-4,162,000$-3,855,000$-3,411,000$-6,288,000$11.23M$-9,069,000$-6,099,000$-828,000$1.62M$6.71M$-5,407,000$-6,307,000
    Interest Income$481,000$128,000$424,000$346,000$380,000$261,000$253,000$462,000$352,000$368,000$571,000$596,000
    Interest Expense$0$0$0$0$0$0$0$0$0$13.06M$0$0
    Income Before Tax$-3,681,000$-3,727,000$-2,987,000$-5,942,000$11.61M$-8,808,000$-5,846,000$-366,000$1.98M$-6,344,000$-4,836,000$-5,711,000
    Income Tax Expense$0$0$0$0$0$0$0$0$-62,500$-85,501$-1$-140,500
    Net Income$-3,681,000$-3,727,000$-2,987,000$-5,942,000$11.61M$-8,808,000$-5,846,000$-366,000$1.98M$-6,344,000$-4,836,000$-5,711,000
    EBITDA$-4,162,000$-3,855,000$-3,411,000$-5,942,000$11.23M$-9,069,000N/A$-490,000$1.62M$6.71M$-5,321,500$-6,307,000
    EBIT$-4,162,000$-3,855,000$-3,411,000$-6,288,000$11.23M$-5,846,000N/A$-828,000$1.62M$-6,712,000$-5,407,000$-6,307,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SLGL

    News

    Sol-Gel Technologies Ltd. - Ordinary Shares (SLGL) Stock Price, News, Quote & History

    This page provides current stock information for Sol-Gel Technologies Ltd. (SLGL), including its last price, change, trading volume, and market capitalization. It also includes an overview of the company...

    FinancialContent•10/15/26•Neutral

    Sol-Gel Eyes 2028 Launch as SGT-610 Nears Pivotal Gorlin Syndrome Data

    Sol-Gel Technologies is preparing for a potential early 2028 launch of SGT-610, a topical treatment for Gorlin syndrome...

    Yahoo Finance•10/14/26•Bullish

    Sol-Gel Technologies Ltd. (IL0011417206.SG) stock price, news, quote and history

    This page provides an overview of Sol-Gel Technologies Ltd. (IL0011417206.SG) stock, including its current price, news, and historical data. The stock is currently trading at 62.50 EUR...

    Yahoo Finance Australia•10/9/26•Neutral

    Sol-Gel Technologies Sets November Shareholder Meeting to Cement Leadership and Expand Capital Base

    Sol-Gel Technologies has called its 2026 annual shareholder meeting for November 17, 2026, to address key governance, leadership, and strategic initiatives. Shareholders will vote on re-electing directors and auditors...

    The Globe and Mail•10/7/26•Somewhat-Bullish

    H.C. Wainwright reiterates Sol Gel stock rating ahead of trial data

    H.C. Wainwright has reiterated a Buy rating and a $110.00 price target for Sol Gel Technologies Ltd. (NASDAQ:SLGL) as the company approaches key trial data for its lead drug candidate, SGT-610. The drug...

    Investing.com•10/6/26•Bullish

    SLGL Valuation and Fair Value

    P/E
    -12.1x
    Forward P/E
    9.3x
    P/B
    4.6x
    See GNG's fair value

    SLGL Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -704.0%
    Net margin
    0.0%
    ROE
    -40.8%
    FCF margin
    -1523.1%

    SLGL Competitors

    CompanyTicker
    Zentalis Pharmaceuticals LlcZNTL
    Greenwich Lifesciences IncGLSI
    Electromed IncELMD
    Spok Holdings IncSPOK
    Lineage Cell Therapeutics IncLCTX
    SIGA Technologies IncSIGA
    High Tide IncHITI
    Pyxis Oncology IncPYXS

    Sector: Healthcare

    SLGL Analyst Ratings

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    0
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    SLGL Bull Case vs Bear Case

    Bear case

    • SLGL's quarterly revenue changed -96.6% year over year.

    SLGL Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    61.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-2.27
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About SLGL

    Does SLGL pay dividends?

    Sol Gel Technologies Ltd (SLGL) does not currently pay a regular dividend.

    What is SLGL's market cap?

    Sol Gel Technologies Ltd (SLGL) has a market capitalization of $227.54M with a current stock price of $68.30.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In